PT2009025E - Método de inibição da actividade dos osteoclastos - Google Patents
Método de inibição da actividade dos osteoclastos Download PDFInfo
- Publication number
- PT2009025E PT2009025E PT08015570T PT08015570T PT2009025E PT 2009025 E PT2009025 E PT 2009025E PT 08015570 T PT08015570 T PT 08015570T PT 08015570 T PT08015570 T PT 08015570T PT 2009025 E PT2009025 E PT 2009025E
- Authority
- PT
- Portugal
- Prior art keywords
- receptors
- osteoclast activity
- inhibiting osteoclast
- isolated
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8548798P | 1998-05-14 | 1998-05-14 | |
US11083698P | 1998-12-03 | 1998-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2009025E true PT2009025E (pt) | 2011-09-19 |
Family
ID=26772773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT08015570T PT2009025E (pt) | 1998-05-14 | 1999-05-13 | Método de inibição da actividade dos osteoclastos |
Country Status (12)
Country | Link |
---|---|
US (2) | US20050089522A1 (pt) |
EP (2) | EP1076699B1 (pt) |
JP (1) | JP2002514418A (pt) |
AT (2) | ATE412746T1 (pt) |
AU (1) | AU762574B2 (pt) |
CA (1) | CA2328140C (pt) |
CY (1) | CY1111912T1 (pt) |
DE (1) | DE69939822D1 (pt) |
DK (1) | DK2009025T3 (pt) |
ES (1) | ES2317694T3 (pt) |
PT (1) | PT2009025E (pt) |
WO (1) | WO1999058674A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
DE122010000046I1 (de) * | 1996-12-13 | 2011-05-05 | Schering Corp | Oberflächenantigene aus Säugern |
EP2371962A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily |
CA2257247C (en) | 1997-04-15 | 2012-09-11 | Snow Brand Milk Products Co., Ltd. | Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same |
CA2285746C (en) * | 1997-04-16 | 2010-09-28 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
WO1998054201A1 (en) * | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
ATE412746T1 (de) | 1998-05-14 | 2008-11-15 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
AU778190B2 (en) * | 1999-07-28 | 2004-11-18 | Trustees Of The University Of Pennsylvania, The | Methods of inhibiting osteoclast activity |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
AU2002231602A1 (en) * | 2001-02-09 | 2002-08-28 | Maxygen Holdings Ltd. | Rank ligand-binding polypeptides |
JP2004526748A (ja) * | 2001-03-22 | 2004-09-02 | バーンズ − ジューウィッシュ・ホスピタル | Rankリガンド融合タンパク質を使用する骨形成の刺激 |
CA2447431A1 (en) | 2001-05-11 | 2002-11-21 | Research Development Foundation | Inhibitors of receptor activator of nf-kb and uses thereof |
WO2002092016A2 (en) * | 2001-05-17 | 2002-11-21 | Immunex Corporation | Therapeutic use of rank antagonists |
SG2011076551A (en) | 2001-06-26 | 2015-08-28 | Amgen Inc | Antibodies to opgl |
CA2463478A1 (en) * | 2001-10-12 | 2003-08-14 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds |
PL375041A1 (en) * | 2002-04-05 | 2005-11-14 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
TW200400830A (en) * | 2002-06-07 | 2004-01-16 | Sankyo Co | A pharmaceutical composition used in the treatment of bone erosion |
TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
CN101772351B (zh) * | 2007-06-05 | 2013-01-02 | 东方酵母工业株式会社 | 新的骨量增加药 |
JP6403999B2 (ja) * | 2014-06-05 | 2018-10-10 | 株式会社細川洋行 | レトルト包装用積層体及び容器 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410516B1 (en) * | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
DE69233051T2 (de) | 1991-10-25 | 2004-03-11 | Immunex Corp., Seattle | Antikörper gegen CD40-L |
DK0672141T3 (da) * | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
US5741667A (en) | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
AU2363695A (en) | 1995-04-27 | 1996-11-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
MX9709447A (es) * | 1995-06-07 | 1998-02-28 | Immunex Corp | Nueva muteina cd4ol. |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
DE122010000046I1 (de) * | 1996-12-13 | 2011-05-05 | Schering Corp | Oberflächenantigene aus Säugern |
EP0951546A2 (en) | 1996-12-20 | 1999-10-27 | The Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
EP2371962A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily |
CA2257247C (en) * | 1997-04-15 | 2012-09-11 | Snow Brand Milk Products Co., Ltd. | Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same |
CA2285746C (en) * | 1997-04-16 | 2010-09-28 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
WO1998049305A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
WO1998054201A1 (en) | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
JPH11266872A (ja) | 1998-03-20 | 1999-10-05 | Suntory Ltd | NF−κBの活性化を抑制する物質のスクリーニング方法 |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
ATE412746T1 (de) | 1998-05-14 | 2008-11-15 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
WO2001003719A2 (en) | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
KR20010085996A (ko) | 1999-09-03 | 2001-09-07 | 스티븐 엠. 오드레 | 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법 |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
JP4401613B2 (ja) | 2000-02-23 | 2010-01-20 | アムジエン・インコーポレーテツド | オステオプロテゲリン結合タンパク質のアンタゴニスト性選択的結合因子 |
WO2002015846A2 (en) | 2000-08-21 | 2002-02-28 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
SG2011076551A (en) | 2001-06-26 | 2015-08-28 | Amgen Inc | Antibodies to opgl |
PL375041A1 (en) | 2002-04-05 | 2005-11-14 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
-
1999
- 1999-05-13 AT AT99923021T patent/ATE412746T1/de not_active IP Right Cessation
- 1999-05-13 DK DK08015570.8T patent/DK2009025T3/da active
- 1999-05-13 DE DE69939822T patent/DE69939822D1/de not_active Expired - Lifetime
- 1999-05-13 JP JP2000548465A patent/JP2002514418A/ja active Pending
- 1999-05-13 AU AU39888/99A patent/AU762574B2/en not_active Expired
- 1999-05-13 ES ES99923021T patent/ES2317694T3/es not_active Expired - Lifetime
- 1999-05-13 PT PT08015570T patent/PT2009025E/pt unknown
- 1999-05-13 EP EP99923021A patent/EP1076699B1/en not_active Expired - Lifetime
- 1999-05-13 CA CA2328140A patent/CA2328140C/en not_active Expired - Lifetime
- 1999-05-13 EP EP08015570A patent/EP2009025B1/en not_active Expired - Lifetime
- 1999-05-13 AT AT08015570T patent/ATE517916T1/de active
- 1999-05-13 WO PCT/US1999/010588 patent/WO1999058674A2/en active IP Right Grant
-
2004
- 2004-11-30 US US10/999,523 patent/US20050089522A1/en not_active Abandoned
-
2008
- 2008-06-11 US US12/137,397 patent/US7790684B2/en not_active Expired - Fee Related
-
2011
- 2011-10-06 CY CY20111100954T patent/CY1111912T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2009025B1 (en) | 2011-07-27 |
CY1111912T1 (el) | 2015-11-04 |
EP1076699B1 (en) | 2008-10-29 |
US20090004196A1 (en) | 2009-01-01 |
EP2009025A1 (en) | 2008-12-31 |
ATE517916T1 (de) | 2011-08-15 |
AU3988899A (en) | 1999-11-29 |
WO1999058674A2 (en) | 1999-11-18 |
US20050089522A1 (en) | 2005-04-28 |
EP1076699A2 (en) | 2001-02-21 |
ES2317694T3 (es) | 2009-04-16 |
AU762574B2 (en) | 2003-06-26 |
WO1999058674A3 (en) | 2000-02-10 |
CA2328140A1 (en) | 1999-11-18 |
DE69939822D1 (de) | 2008-12-11 |
DK2009025T3 (da) | 2011-11-14 |
JP2002514418A (ja) | 2002-05-21 |
ATE412746T1 (de) | 2008-11-15 |
US7790684B2 (en) | 2010-09-07 |
CA2328140C (en) | 2012-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2009025E (pt) | Método de inibição da actividade dos osteoclastos | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
PL349028A1 (en) | Cancer treatment composition and method using natural plant essential oils | |
UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
IL139355A (en) | 24-hydroxyvitamin d, analogs and uses thereof | |
PL347469A1 (en) | Use of certain drugs for treating nerve root injury | |
AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
WO2001043732A3 (en) | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies | |
WO2000015205A3 (en) | Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
BG105275A (en) | Tan-1057 derivatives | |
AU8020698A (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
ATE238986T1 (de) | 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga | |
WO2001080894A3 (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
HUP0000954A3 (en) | Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy | |
HUP9900007A2 (hu) | Készítmény baromfialom kezelésére | |
AUPP379698A0 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions | |
HUP0101602A2 (hu) | Termékenységet javító készítmény, és annak alkalmazása | |
AU2002357691A1 (en) | Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 | |
FR2745179B1 (fr) | Melange maitre actif pour la preparation d'une composition dermocosmetique, composition dermocosmetique contenant ce melange, et methode pour la preparation de ce melange | |
HU9802142D0 (en) | Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system |